Fig. 1: Upregulation of NNMT in EGFR-TKI-resistant NSCLC cells. | Cell Death Discovery

Fig. 1: Upregulation of NNMT in EGFR-TKI-resistant NSCLC cells.

From: Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells

Fig. 1: Upregulation of NNMT in EGFR-TKI-resistant NSCLC cells.

A EGFR-TKI-resistant PC9/GR and parental PC9 cells were treated with gefitinib or erlotinib at the indicated concentration for 72 h, cell viability was evaluated by MTS assay. B iTRAQ-based quantitative proteomic comparison of PC9/GR cells and PC9 cells, experimental workflow showing the trypsin digestion, iTRAQ-labeling, and detection by tandem mass spectrometry. The acquired data was used to search a bioinformatics database. C Volcano plot showing the log2 fold-change and significance (−log10 p-value) of the proteome dataset. Red dots represent significantly upregulated proteins, blue dots represent significantly downregulated proteins. D Hierarchical clustering of top 20 differentially expressed proteins. E Validation of NNMT expression in EGFR-TKI-resistant PC9/GR, HCC827/GR, and parental PC9, HCC827 cells by Western blot. F NNMT specific activity in PC9/GR, HCC827/GR, PC9, and HCC827 cells was tested by measuring the amount of N1-methylnicotinamide produced. Each point represents the mean ± SD. Data show a representative of three independent experiments. (**p < 0.01).

Back to article page